Shanghai-based biotechnology company developing natural and gene-modified tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors
Shanghai-based biotechnology company developing natural and gene-modified tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its DeepTIL cell-expansion platform aims to produce potent TIL therapies with reduced reliance on high-dose IL-2 and less intensive pretreatment, while its NovaGMP platform enables non-viral gene modification. Its pipeline includes therapies for multiple cancers, including melanoma, lung, ovarian, pancreatic, cervical, endometrial, bile duct, brain, and,